These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27798619)

  • 1. Protective neutralizing influenza antibody response in the absence of T follicular helper cells.
    Miyauchi K; Sugimoto-Ishige A; Harada Y; Adachi Y; Usami Y; Kaji T; Inoue K; Hasegawa H; Watanabe T; Hijikata A; Fukuyama S; Maemura T; Okada-Hatakeyama M; Ohara O; Kawaoka Y; Takahashi Y; Takemori T; Kubo M
    Nat Immunol; 2016 Dec; 17(12):1447-1458. PubMed ID: 27798619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
    Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
    Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies.
    Keating R; Johnson JL; Brice DC; Labombarde JG; Dent AL; McGargill MA
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity.
    Seo YB; Im SJ; Namkoong H; Kim SW; Choi YW; Kang MC; Lim HS; Jin HT; Yang SH; Cho ML; Kim YM; Lee SW; Choi YK; Surh CD; Sung YC
    J Virol; 2014 Aug; 88(16):8998-9009. PubMed ID: 24899182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
    Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice.
    Nguyen HH; van Ginkel FW; Vu HL; Novak MJ; McGhee JR; Mestecky J
    J Virol; 2000 Jun; 74(12):5495-501. PubMed ID: 10823854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
    Prabakaran M; Kolpe AB; He F; Kwang J
    Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice.
    Wen Z; Wang X; Dong K; Zhang H; Bu Z; Ye L; Yang C
    Microbes Infect; 2017 Dec; 19(12):626-634. PubMed ID: 28899815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High T
    Eldi P; Chaudhri G; Nutt SL; Newsome TP; Karupiah G
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.